Shares of Natus Medical Inc (NASDAQ:BABY) have been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $36.00.
Several brokerages recently weighed in on BABY. Zacks Investment Research downgraded shares of Natus Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, February 15th. ValuEngine downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. BidaskClub downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. Finally, William Blair restated a “market perform” rating on shares of Natus Medical in a research report on Saturday, January 12th.
Get Natus Medical alerts:
BABY traded up $0.07 during trading hours on Friday, reaching $27.06. 282,938 shares of the stock traded hands, compared to its average volume of 455,427. The firm has a market cap of $915.10 million, a price-to-earnings ratio of 19.06 and a beta of 0.54. Natus Medical has a fifty-two week low of $25.06 and a fifty-two week high of $37.95. The company has a current ratio of 2.14, a quick ratio of 1.54 and a debt-to-equity ratio of 0.17.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, February 13th. The medical equipment provider reported $0.43 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by ($0.07). The business had revenue of $141.00 million during the quarter, compared to analyst estimates of $135.80 million. Natus Medical had a negative net margin of 4.32% and a positive return on equity of 11.64%. The company’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period last year, the firm posted $0.42 earnings per share. On average, analysts forecast that Natus Medical will post 1.25 earnings per share for the current fiscal year.
In other news, Director Robert A. Gunst sold 6,304 shares of Natus Medical stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $27.96, for a total value of $176,259.84. Following the transaction, the director now owns 32,392 shares of the company’s stock, valued at approximately $905,680.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert A. Gunst sold 8,304 shares of Natus Medical stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $28.09, for a total transaction of $233,259.36. Following the completion of the transaction, the director now directly owns 32,392 shares in the company, valued at approximately $909,891.28. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Paloma Partners Management Co purchased a new position in shares of Natus Medical in the third quarter worth approximately $218,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Natus Medical by 51.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,495 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 845 shares in the last quarter. Vaughan Nelson Investment Management L.P. purchased a new position in shares of Natus Medical in the fourth quarter worth approximately $33,985,000. Rutabaga Capital Management LLC MA purchased a new position in shares of Natus Medical in the third quarter worth approximately $9,272,000. Finally, MetLife Investment Advisors LLC increased its position in shares of Natus Medical by 52.4% in the third quarter. MetLife Investment Advisors LLC now owns 23,094 shares of the medical equipment provider’s stock worth $823,000 after acquiring an additional 7,937 shares in the last quarter. 98.37% of the stock is currently owned by institutional investors.
About Natus Medical
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Story: Trading Ex-Dividend